


Express Mail Label No. ET318104199US

Date of Deposit: November 26, 2001

Attorney Docket No. 22058-521



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.  
SERIAL NUMBER: 09/521,696  
FILING DATE: March 9, 2000  
FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity  
EXAMINER: J. Seharaseyon  
ART UNIT: 1647

RECEIVED

NOV 30 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box RCE

12/a  
11.9.1  
12/4/01

AMENDMENT ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

In response to the Office Action mailed May 24, 2001 ("Office Action"), please amend the application as follows:

In the specification:

Insert at page 1, line 2 after the title:

--RELATED APPLICATIONS

a<sup>1</sup> This application claims priority to USSN 60/124,024, filed March 11, 1999. The contents of this application are incorporated herein by reference in their entirety.

Repln. Ref: 11/30/2001 GTEFFERA 0016080700  
DAH:500311 Name/Number:09521696  
FC: 704 \$60.00 CR

In the claims:

1. (Amended) A method of preventing [an immune-mediated disorder] complement-mediated cytotoxicity in a mammal which comprises  
identifying a mammal at risk of developing complement-mediated cytotoxicity; and

11/30/2001 GTEFFERA 00000016 09521696

01 FC:102

84.00 GP